Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Natus Medical Inc    BABY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Natus Medical Inc : Natus Medical to Hold 2012 First Quarter Financial Results Conference Call on April 26

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2012 | 01:05pm CEST

Natus Medical Incorporated (NASDAQ:BABY) today announced that the Company intends to release its 2012 first quarter financial results before the market opens on Thursday, April 26, 2012. Natus management will host an investment-community conference call the same day beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) to discuss those results and to answer questions.

Individuals interested in listening to the conference call may do so by dialing 888-268-4176 for domestic callers, or 1-617-597-5493 for international callers, and entering reservation code 32875965. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 888-286-8010 for domestic callers, or 1-617-801-6888 for international callers, and entering reservation code 56980616.

The conference call also will be available real-time via the Internet at http://investor.natus.com, and a recording of the call will be available on the Company's Web site for 90 days following the completion of the call.

About Natus Medical Incorporated

Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories.

Additional information about Natus Medical can be found at www.natus.com.

Natus Medical Incorporated
Steven J. Murphy, 650-802-0400
[email protected]
Vice President and Chief Financial Officer


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NATUS MEDICAL INC
10/11 Natus Medical to Hold 2017 Third Quarter Financial Results Conference Call on..
10/09 NATUS MEDICAL INCORPORATED (NASDAQ : BABY) Files An 8-K Completion of Acquisitio..
10/07 NATUS MEDICAL : Nordea Investment Management AB Raises Holdings in Natus Medical..
10/06 NATUS MEDICAL INC : Completion of Acquisition or Disposition of Assets, Financia..
10/06 Natus Completes Acquisition of Neurosurgery Assets from Integra LifeSciences
09/12 NATUS MEDICAL : to Acquire Neurosurgery Assets from Integra LifeSciences, Enters..
09/11 NATUS MEDICAL INCORPORATED (NASDAQ : BABY) Files An 8-K Entry into a Material De..
09/11 NATUS MEDICAL INC : Entry into a Material Definitive Agreement, Financial Statem..
09/11 Natus to Acquire Neurosurgery Assets from Integra LifeSciences, Enters Neuros..
09/02 NATUS MEDICAL : $34,729 Federal Contract Awarded to Natus Medical
More news
News from SeekingAlpha
10/06 Natus completes acquisition of neurosurgery assets from Integra
09/11 Natus Medical to buy neurosurgery assets from Integra for $47.5M; shares ahea..
07/26 Natus Medical's (BABY) CEO James Hawkins on Q2 2017 Results - Earnings Call T..
07/26 Natus Medical Q2 revenues up 27%; updates guidance
07/26 Natus Medical beats by $0.01, beats on revenue
Financials ($)
Sales 2017 505 M
EBIT 2017 76,0 M
Net income 2017 22,4 M
Debt 2017 37 027 M
Yield 2017 -
P/E ratio 2017 58,00
P/E ratio 2018 25,50
Capi. / Sales 2017 75,8x
Capi. / Sales 2018 2,55x
Capitalization 1 298 M
Chart NATUS MEDICAL INC
Duration : Period :
Natus Medical Inc Technical Analysis Chart | BABY | US6390501038 | 4-Traders
Technical analysis trends NATUS MEDICAL INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 49,5 $
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
James B. Hawkins President, Chief Executive Officer & Director
Robert A. Gunst Chairman
Jonathan A. Kennedy Chief Financial Officer & Executive Vice President
D. Christopher Chung VP-Medical Affairs, Quality & Regulatory
Doris E. Engibous Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NATUS MEDICAL INC15.23%1 298
THERMO FISHER SCIENTIFIC INC.36.37%75 299
DANAHER11.56%59 229
BOSTON SCIENTIFIC CORPORATION36.11%40 341
INTUITIVE SURGICAL71.38%39 566
ROYAL PHILIPS19.34%38 039